Skip to content

Keenova Therapeutics plc

CIK 0001567892

← back to feed
Revenue (TTM)
$1.91B
+32.0% YoY Q1 May 2026
Net Income (TTM)
−$429.9M
−202.4% YoY Q1 May 2026
EPS Diluted (TTM)
−$13.17
−172.4% YoY Q1 May 2026
Gross Margin
41.0%
Q1 May 2026
Operating Margin
-17.8%
Q1 May 2026
Net Margin
-22.5%
Q1 May 2026
Free Cash Flow (TTM)
$166.3M
Q1 May 2026
Cash
$824.9M
Q1 May 2026
Total Debt
$1.66B
Q1 May 2026
Shares Outstanding
39.58M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings